» Articles » PMID: 30108680

Exosomes Derived from Cancerous and Non-cancerous Cells Regulate the Anti-tumor Response in the Tumor Microenvironment

Overview
Journal Genes Cancer
Specialty Oncology
Date 2018 Aug 16
PMID 30108680
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

The tumor microenvironment (TME) is a unique platform of cancer biology that considers the local cellular environment in which a tumor exists. Increasing evidence points to the TME as crucial for either promoting immune tumor rejection or protecting the tumor. The TME includes surrounding blood vessels, the extracellular matrix (ECM), a variety of immune and regulatory cells, and signaling factors. Exosomes have emerged to be molecular contributors in cancer biology, and to modulate and affect the constituents of the TME. Exosomes are small (40-150 nm) membrane vesicles that are derived from an endocytic nature and are later excreted by cells. Depending on the cells from which they originate, exosomes can play a role in tumor suppression or tumor progression. Tumor-derived exosomes (TDEs) have their own unique phenotypic functions. Evidence points to TDEs as key players involved in tumor growth, tumorigenesis, angiogenesis, dysregulation of immune cells and immune escape, metastasis, and resistance to therapies, as well as in promoting anti-tumor response. General exosomes, TDEs, and their influence on the TME are an area of promising research that may provide potential biomarkers for therapy, potentiation of anti-tumor response, development of exosome-based vaccines, and exosome-derived nanocarriers for drugs.

Citing Articles

Free energy calculations for membrane morphological transformations and insights to physical biology and oncology.

Parihar K, Ko S, Bradley R, Taylor P, Ramakrishnan N, Baumgart T Methods Enzymol. 2024; 701:359-386.

PMID: 39025576 PMC: 11258396. DOI: 10.1016/bs.mie.2024.03.028.


Asymmetric crowders and membrane morphology at the nexus of intracellular trafficking and oncology.

Parihar K, Ko S, Bradley R, Taylor P, Ramakrishnan N, Baumgart T Mechanobiol Med. 2024; 2(3).

PMID: 38899029 PMC: 11185830. DOI: 10.1016/j.mbm.2024.100071.


Exosome may be the next generation of promising cell-free vaccines.

Dai Z, Cai R, Zeng H, Zhu H, Dou Y, Sun S Hum Vaccin Immunother. 2024; 20(1):2345940.

PMID: 38714324 PMC: 11086043. DOI: 10.1080/21645515.2024.2345940.


Exosomal non-coding RNAs: Blueprint in colorectal cancer metastasis and therapeutic targets.

Hussen B, Abdullah S, Abdullah S, Younis Y, Hidayat H, Rasul M Noncoding RNA Res. 2023; 8(4):615-632.

PMID: 37767111 PMC: 10520679. DOI: 10.1016/j.ncrna.2023.09.001.


Recent progress in molecular mechanisms of postoperative recurrence and metastasis of hepatocellular carcinoma.

Niu Z, Wang W, Niu X World J Gastroenterol. 2022; 28(46):6433-6477.

PMID: 36569275 PMC: 9782839. DOI: 10.3748/wjg.v28.i46.6433.


References
1.
Lee C, Chiang Y, Chang S, Chong C, Cheng B, Roffler S . Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses. Clin Cancer Res. 2009; 15(8):2756-66. DOI: 10.1158/1078-0432.CCR-08-2311. View

2.
Liu Y, Xiang X, Zhuang X, Zhang S, Liu C, Cheng Z . Contribution of MyD88 to the tumor exosome-mediated induction of myeloid derived suppressor cells. Am J Pathol. 2010; 176(5):2490-9. PMC: 2861113. DOI: 10.2353/ajpath.2010.090777. View

3.
Zhu L, Kalimuthu S, Gangadaran P, Oh J, Lee H, Baek S . Exosomes Derived From Natural Killer Cells Exert Therapeutic Effect in Melanoma. Theranostics. 2017; 7(10):2732-2745. PMC: 5558565. DOI: 10.7150/thno.18752. View

4.
Dittmer J, Leyh B . The impact of tumor stroma on drug response in breast cancer. Semin Cancer Biol. 2014; 31:3-15. DOI: 10.1016/j.semcancer.2014.05.006. View

5.
Bobrie A, Krumeich S, Reyal F, Recchi C, Moita L, Seabra M . Rab27a supports exosome-dependent and -independent mechanisms that modify the tumor microenvironment and can promote tumor progression. Cancer Res. 2012; 72(19):4920-30. DOI: 10.1158/0008-5472.CAN-12-0925. View